Trimtech Therapeutics
Last verified 2026-04-29. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $31.0Mattributed |
|---|---|
| Latest round | seed, $31.0M, 2025-03-01attributed |
| Founded | unknown |
| Headquarters | GB |
| Industry | bio |
| Stage | seed |
| Website | trimtechtherapeutics.com |
Trimtech Therapeutics develops targeted protein degraders, branded TRIMTACs and TRIMGLUEs, that selectively remove disease-causing proteins to treat CNS and inflammatory disorders. It is built for patients with intractable disease driven by toxic protein buildup. Its programs use TRIM21, a widely expressed but underused ubiquitin ligase.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-03-01 | seed | $31.0M | undisclosed |
Detected tech stack
WordPress 7.0, Yoast SEO 27.6, Google Analytics, Google Tag Manager, jQuery Migrate 3.4.1, parallax.js, DoubleClick Floodlight, CookieYes, PHP, MySQL, jquery 3.7.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $31.0M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $31.0M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | trimtechtherapeutics.com, read 2026-04-29 |
| Description | self-reported | trimtechtherapeutics.com, read 2026-04-29 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.